Enzon Pharmaceuticals, Inc. (ENZN)
| Market Cap | 22.24M |
| Revenue (ttm) | 320,000 |
| Net Income (ttm) | -771,000 |
| Shares Out | 74.21M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 0.300 |
| Previous Close | 0.300 |
| Day's Range | 0.300 - 0.300 |
| 52-Week Range | 0.250 - 0.760 |
| Beta | -0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ENZN
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Financial Performance
In 2021, ENZN's revenue was $701,000, an increase of 1,248.08% compared to the previous year's $52,000. Losses were -$469,000, -64.23% less than in 2020.
Financial StatementsNews
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CE...
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Compa...
Enzon Pharmaceuticals Announces Results of Rights Offering
Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting”)...
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders
CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights off...
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value
CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits pre...